175 related articles for article (PubMed ID: 18060075)
1. Effects of blood collection conditions on ovarian cancer serum markers.
Thorpe JD; Duan X; Forrest R; Lowe K; Brown L; Segal E; Nelson B; Anderson GL; McIntosh M; Urban N
PLoS One; 2007 Dec; 2(12):e1281. PubMed ID: 18060075
[TBL] [Abstract][Full Text] [Related]
2. A combined blood based gene expression and plasma protein abundance signature for diagnosis of epithelial ovarian cancer--a study of the OVCAD consortium.
Pils D; Tong D; Hager G; Obermayr E; Aust S; Heinze G; Kohl M; Schuster E; Wolf A; Sehouli J; Braicu I; Vergote I; Van Gorp T; Mahner S; Concin N; Speiser P; Zeillinger R
BMC Cancer; 2013 Apr; 13():178. PubMed ID: 23551967
[TBL] [Abstract][Full Text] [Related]
3. [Evaluation of selected serum protein markers as early detectors of ovarian cancer].
Mrochem J; Sodowski K; Deja R; Walaszek-Gruszka A; Wojcieszek A; Kołosza Z; Chmura A; Czernik E; Masłyk B; Bartnik W; Cnota W
Ginekol Pol; 2008 Apr; 79(4):271-5. PubMed ID: 18592865
[TBL] [Abstract][Full Text] [Related]
4. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.
Shah CA; Lowe KA; Paley P; Wallace E; Anderson GL; McIntosh MW; Andersen MR; Scholler N; Bergan LA; Thorpe JD; Urban N; Drescher CW
Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1365-72. PubMed ID: 19423517
[TBL] [Abstract][Full Text] [Related]
5. Combination of serum biomarkers to differentiate malignant from benign ovarian tumours.
He G; Holcroft CA; Beauchamp MC; Yasmeen A; Ferenczy A; Kendall-Dupont J; Mes-Masson AM; Provencher D; Gotlieb WH
J Obstet Gynaecol Can; 2012 Jun; 34(6):567-574. PubMed ID: 22673173
[TBL] [Abstract][Full Text] [Related]
6. Comparison of candidate serologic markers for type I and type II ovarian cancer.
Lu D; Kuhn E; Bristow RE; Giuntoli RL; Kjær SK; Shih IeM; Roden RB
Gynecol Oncol; 2011 Sep; 122(3):560-6. PubMed ID: 21704359
[TBL] [Abstract][Full Text] [Related]
7. The diagnostic value of macrophage migration inhibitory factor (MIF) in gastric cancer.
Camlica H; Duranyildiz D; Oguz H; Oral EN; Yasasever V
Pathol Oncol Res; 2008 Mar; 14(1):79-83. PubMed ID: 18347935
[TBL] [Abstract][Full Text] [Related]
8. Autoantibody biomarkers identified by proteomics methods distinguish ovarian cancer from non-ovarian cancer with various CA-125 levels.
Karabudak AA; Hafner J; Shetty V; Chen S; Secord AA; Morse MA; Philip R
J Cancer Res Clin Oncol; 2013 Oct; 139(10):1757-70. PubMed ID: 23999876
[TBL] [Abstract][Full Text] [Related]
9. Alternatives to risk-reducing surgery for ovarian cancer.
Gadducci A; Sergiampietri C; Tana R
Ann Oncol; 2013 Nov; 24 Suppl 8():viii47-viii53. PubMed ID: 24131970
[TBL] [Abstract][Full Text] [Related]
10. Validation of a Novel Biomarker Panel for the Detection of Ovarian Cancer.
Leung F; Bernardini MQ; Brown MD; Zheng Y; Molina R; Bast RC; Davis G; Serra S; Diamandis EP; Kulasingam V
Cancer Epidemiol Biomarkers Prev; 2016 Sep; 25(9):1333-40. PubMed ID: 27448593
[TBL] [Abstract][Full Text] [Related]
11. Macrophage migration inhibitory factor predicts an unfavorable outcome after transarterial chemoembolization for hepatic malignancies.
Wirtz TH; Loosen SH; Schulze-Hagen M; Gorgulho J; Kandler J; Joerdens M; Demir M; Mohr R; Bruners P; Kuhl C; Trautwein C; Berres ML; Tacke F; Luedde T; Roderburg C
Clin Transl Sci; 2021 Sep; 14(5):1853-1863. PubMed ID: 33787014
[TBL] [Abstract][Full Text] [Related]
12. Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients.
Leung F; Dimitromanolakis A; Kobayashi H; Diamandis EP; Kulasingam V
Clin Biochem; 2013 Oct; 46(15):1462-8. PubMed ID: 23528302
[TBL] [Abstract][Full Text] [Related]
13. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
[TBL] [Abstract][Full Text] [Related]
14. A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer.
Zhu CS; Pinsky PF; Cramer DW; Ransohoff DF; Hartge P; Pfeiffer RM; Urban N; Mor G; Bast RC; Moore LE; Lokshin AE; McIntosh MW; Skates SJ; Vitonis A; Zhang Z; Ward DC; Symanowski JT; Lomakin A; Fung ET; Sluss PM; Scholler N; Lu KH; Marrangoni AM; Patriotis C; Srivastava S; Buys SS; Berg CD;
Cancer Prev Res (Phila); 2011 Mar; 4(3):375-83. PubMed ID: 21372037
[TBL] [Abstract][Full Text] [Related]
15. Do preoperative serum vascular endothelial growth factor and migration-inhibitory factor predict the nature of the adnexal masses? A prospective-controlled trial.
Yildirim N; Dikmen Y; Terek MC; Akman L; Gunel NS; Aktan C; Zekioglu O; Gunduz C
J Obstet Gynaecol; 2016 May; 36(4):533-7. PubMed ID: 26758243
[TBL] [Abstract][Full Text] [Related]
16. Serum biomarker profiles as diagnostic tools in lung cancer.
Nolen BM; Langmead CJ; Choi S; Lomakin A; Marrangoni A; Bigbee WL; Weissfeld JL; Wilson DO; Dacic S; Siegfried JM; Lokshin AE
Cancer Biomark; 2011-2012; 10(1):3-12. PubMed ID: 22297547
[TBL] [Abstract][Full Text] [Related]
17. Measurement of phospholipids may improve diagnostic accuracy in ovarian cancer.
Shan L; Chen YA; Davis L; Han G; Zhu W; Molina AD; Arango H; LaPolla JP; Hoffman MS; Sellers T; Kirby T; Nicosia SV; Sutphen R
PLoS One; 2012; 7(10):e46846. PubMed ID: 23082132
[TBL] [Abstract][Full Text] [Related]
18. A multiplex biomarker assay improves the diagnostic performance of HE4 and CA125 in ovarian tumor patients.
Leandersson P; Åkesson A; Hedenfalk I; Malander S; Borgfeldt C
PLoS One; 2020; 15(10):e0240418. PubMed ID: 33075095
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic markers for early detection of ovarian cancer.
Visintin I; Feng Z; Longton G; Ward DC; Alvero AB; Lai Y; Tenthorey J; Leiser A; Flores-Saaib R; Yu H; Azori M; Rutherford T; Schwartz PE; Mor G
Clin Cancer Res; 2008 Feb; 14(4):1065-72. PubMed ID: 18258665
[TBL] [Abstract][Full Text] [Related]
20. Validation of LRG1 as a potential biomarker for detection of epithelial ovarian cancer by a blinded study.
Wu J; Yin H; Zhu J; Buckanovich RJ; Thorpe JD; Dai J; Urban N; Lubman DM
PLoS One; 2015; 10(3):e0121112. PubMed ID: 25799488
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
